Search Results

You are looking at 211 - 220 of 530 items for :

  • "pathology" x
  • Refine by Access: All x
Clear All
Full access

Antoine Eskander, Qing Li, Jiayue Yu, Julie Hallet, Natalie G. Coburn, Anna Dare, Kelvin K.W. Chan, Simron Singh, Ambica Parmar, Craig C. Earle, Lauren Lapointe-Shaw, Monika K. Krzyzanowska, Timothy P. Hanna, Antonio Finelli, Alexander V. Louie, Nicole Look Hong, Jonathan C. Irish, Ian J. Witterick, Alyson Mahar, Christopher W. Noel, David R. Urbach, Daniel I. McIsaac, Danny Enepekides, and Rinku Sutradhar

from September 25, 2016, to September 26, 2020, were identified using the Ontario Cancer Registry (OCR); this database consists of all cancers diagnosed in the province since 1964 and has a >95% capture of incident cancers. 14 , 15 All pathology

Full access

Karen L. Rech and Rong He

conditions. The diagnosis requires multidisciplinary integration of the entire picture from the clinical, radiology, laboratory, and pathology perspectives. Clinical Presentation The presenting signs and symptoms of histiocytic neoplasms are diverse, and

Full access

Zachary Veitch, Omar F. Khan, Derek Tilley, Domen Ribnikar, Xanthoula Kostaras, Karen King, Patricia Tang, and Sasha Lupichuk

Cancer Registry (ACR). Patients were stratified into 2 cohorts: those with (1) node-negative disease who received DCH or TCH or (2) node-positive disease who received FEC-DH or TCH ( Figure 1 ). Patient and pathology characteristics (Tables 1 and 2

Full access

Silviya K. Meletath, Dean Pavlick, Tim Brennan, Roy Hamilton, Juliann Chmielecki, Julia A. Elvin, Norma Palma, Jeffrey S. Ross, Vincent A. Miller, Philip J. Stephens, George Snipes, Veena Rajaram, Siraj M. Ali, and Isaac Melguizo-Gavilanes

pathology report noted features of ganglioglioma with mixed neuronal and glial growth patterns. In regions of the tumor with an abundant glial component, there was evidence of moderate cell proliferation as assessed by Ki-67 (MIB-1) immunohistochemistry (A

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

, HER2 tumor status determination, and pathology review. Use of MRI is optional and is not universally recommended by experts in the field. Breast MRI advocates note its high sensitivity for evaluation of extent of disease, particularly for invasive

Full access

Jarred Burkart, Dwight Owen, Manisha H. Shah, Sherif R. Z. Abdel-Misih, Sameek Roychowdhury, Robert Wesolowski, Sigurdis Haraldsdottir, Julie W. Reeser, Eric Samorodnitsky, Amy Smith, and Bhavana Konda

. Pathology revealed omentum with acute inflammation and abscess formation, with no evidence of malignancy in 13 lymph nodes. He recovered from surgery and was discontinued from the trial, but continued on single-agent dabrafenib due to the BRAF V600E

Full access

Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, and Ganessan Kichenadasse

tumor from the diaphragm and Gerota fascia. There was no evidence of disease on postoperative imaging. Surgical pathology showed a high-grade serous carcinoma of endometrial origin with the bulk of the tumor arising from the lower fundus, lower uterine

Full access

Brian J. Williams, Daniel M.S. Raper, Erin Godbout, T. David Bourne, Daniel M. Prevedello, Amin B. Kassam, and Deric M. Park

against chordoma. 46 Finally, brachyury, a histologic marker for chordoma, may also drive chordoma pathology. Transient genetic knockdown of brachyury in chordoma cells was found to induce differentiation and senescence. 47 Furthermore, brachyury has

Full access

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021

Featured Updates to the NCCN Guidelines

Nadeem R. Abu-Rustum, Catheryn M. Yashar, Kristin Bradley, Susana M. Campos, Junzo Chino, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Elisabeth Diver, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Robert Giuntoli II, Ernest Han, Brooke Howitt, Warner K. Huh, Jayanthi Lea, Andrea Mariani, David Mutch, Larissa Nekhlyudov, Mirna Podoll, Steven W. Remmenga, R. Kevin Reynolds, Ritu Salani, Rachel Sisodia, Pamela Soliman, Edward Tanner, Stefanie Ueda, Renata Urban, Stephanie L. Wethington, Emily Wyse, Kristine Zanotti, Nicole R. McMillian, and Angela D. Motter

of Pathology and Molecular Analysis section of the Uterine Sarcoma Guidelines in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Uterine Neoplasms. In addition to the introductory page ( UTSARC-A 1 of 5 , above), this section

Full access

George Handzo, Jill M. Bowden, and Stephen King

publication of the third edition of the NCP guidelines. The panel chose “distress” as the focus of the 1997 NCCN Guidelines because that term did not represent or infer any kind of pathology. Efforts were made to describe distress as a normally expected